These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 19776622)

  • 1. Dietary modulators of peroxisome proliferator-activated receptors: implications for the prevention and treatment of metabolic syndrome.
    Guri AJ; Hontecillas R; Bassaganya-Riera J
    J Nutrigenet Nutrigenomics; 2008; 1(3):126-35. PubMed ID: 19776622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptors: bridging metabolic syndrome with molecular nutrition.
    Guri AJ; Hontecillas R; Bassaganya-Riera J
    Clin Nutr; 2006 Dec; 25(6):871-85. PubMed ID: 17052808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The metabolic syndrome: relationship between insulin sensitivity and the role of peroxisome proliferator-activated receptors (PPARs) in saccharide and lipid metabolism.
    Yahia RB; Lichnovská R; Brychta T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):237-41. PubMed ID: 16601762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development].
    Alemán G; Torres N; Tovar AR
    Rev Invest Clin; 2004; 56(3):351-67. PubMed ID: 15612519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary regulation of nuclear receptors in obesity-related metabolic syndrome.
    Kawada T; Goto T; Hirai S; Kang MS; Uemura T; Yu R; Takahashi N
    Asia Pac J Clin Nutr; 2008; 17 Suppl 1():126-30. PubMed ID: 18296319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease.
    Smith AG; Muscat GE
    Int J Biochem Cell Biol; 2005 Oct; 37(10):2047-63. PubMed ID: 15922648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
    Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome.
    Guan Y
    J Am Soc Nephrol; 2004 Nov; 15(11):2801-15. PubMed ID: 15504933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor: effects on nutritional homeostasis, obesity and diabetes mellitus.
    Viana Abranches M; Esteves de Oliveira FC; Bressan J
    Nutr Hosp; 2011; 26(2):271-9. PubMed ID: 21666962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
    Gervois P; Fruchart JC; Staels B
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome.
    Fernandez AZ
    Curr Opin Investig Drugs; 2004 Sep; 5(9):936-40. PubMed ID: 15503647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceramides in insulin resistance and lipotoxicity.
    Summers SA
    Prog Lipid Res; 2006 Jan; 45(1):42-72. PubMed ID: 16445986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPAR agonists and the metabolic syndrome.
    Staels B
    Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
    Giaginis C; Tsantili-Kakoulidou A; Theocharis S
    Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptors and the metabolic syndrome.
    Bragt MC; Popeijus HE
    Physiol Behav; 2008 May; 94(2):187-97. PubMed ID: 18191967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioactive lipids in metabolic syndrome.
    Nagao K; Yanagita T
    Prog Lipid Res; 2008 Mar; 47(2):127-46. PubMed ID: 18177744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases.
    Yamauchi T; Kadowaki T
    Int J Obes (Lond); 2008 Dec; 32 Suppl 7():S13-8. PubMed ID: 19136982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy.
    Chinetti-Gbaguidi G; Fruchart JC; Staels B
    Curr Opin Pharmacol; 2005 Apr; 5(2):177-83. PubMed ID: 15780828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.
    Pirat C; Farce A; Lebègue N; Renault N; Furman C; Millet R; Yous S; Speca S; Berthelot P; Desreumaux P; Chavatte P
    J Med Chem; 2012 May; 55(9):4027-61. PubMed ID: 22260081
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.